Citius Pharmaceuticals Investor Relations Material
Latest events
Investor Update
Citius Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Citius Pharmaceuticals Inc
Access all reports
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products. The company's pipeline includes a range of therapeutic candidates targeting various medical needs. Key products include Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections, and LYMPHIR, a targeted immunotherapy recently approved by the FDA for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). Another notable product is CITI-002 (Halo-Lido), a topical formulation aimed at providing relief for hemorrhoids. The company is based in Cranford, New Jersey, and its shares are traded on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
CTXR
Country
🇺🇸 United States